Quarterly ResultOct 5, 2026, 04:12 PM
AbbVie Q3 2026 EPS Guidance Lowered by $0.11 Due to $216M Expense
AI Summary
AbbVie Inc. announced preliminary results for the third quarter of 2026, expecting acquired IPR&D and milestones expense of $216 million, which will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.11. The company updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.76 - $13.96 and its third-quarter 2026 adjusted diluted EPS guidance to $3.73 - $3.77, reflecting this expense. AbbVie noted that acquired IPR&D and milestones expense is not typically forecasted due to the uncertainty of future transactions.
Key Highlights
- AbbVie's Q3 2026 adjusted diluted EPS guidance range is $3.73 - $3.77, including $216 million in acquired IPR&D and milestones expense.
- AbbVie's full-year 2026 adjusted diluted EPS guidance range is $13.76 - $13.96, including $216 million in acquired IPR&D and milestones expense.
- Acquired IPR&D and milestones expense of $216 million represents an unfavorable impact of $0.11 on both GAAP and adjusted non-GAAP diluted EPS for Q3 2026.
- Previously announced full-year 2026 adjusted diluted EPS guidance range (excluding Q3 expense) was $13.87 - $14.07.
- Previously announced Q3 2026 adjusted diluted EPS guidance range (excluding Q3 expense) was $3.84 - $3.88.
Price Impact
More from ABBV